Prospective observational study to develop and validate a risk prediction model for taxane-induced peripheral neuropathy in early-stage cancer

Taxane-induced peripheral neuropathy (TIPN) affects quality of life and ability to complete cancer treatment. Results from the prospective observational SWOG S1714 cohort study were analyzed to develop and validate a risk prediction model for TIPN in stage I to III lung, breast, ovarian, fallopian tube, or primary peritoneal cancer in adult patients who were starting taxane-based treatment. Among 1278 patients (median age 55.0 years; range 23.0-84.0), 804 (62.9%) experienced TIPN by week 24. A two-step training and test approach was used to derive a TIPN risk prediction model. The model included 5 adverse risk factors: receipt of paclitaxel; stage II or III disease; planned taxane duration of more than 12 weeks; diabetes, autoimmune disease, moderate kidney disease, or a neurologic condition; and self-identified race and ethnicity (Black, Hispanic, Native American, Pacific Islander, unknown). This model predicted disparate levels of TIPN risk. The authors conclude that the risk prediction model may guide treatment decision-making, symptom monitoring, and supportive care.